Results 131 to 140 of about 1,106,189 (267)
The Mechanisms and Application Prospects of Astrocyte Reprogramming into Neurons in Central Nervous System Diseases. [PDF]
Qin R +6 more
europepmc +1 more source
Objective This study aimed to characterize cannabis product choices (cannabinoid content and formulation) among patients with rheumatologic conditions and their associations with patient factors, patient‐reported perceived side effects, and positive impacts.
Susan Zhang +10 more
wiley +1 more source
Exploring the Neuroprotective Potential of <i>Astragalus membranaceus</i> in Central Nervous System Diseases. [PDF]
Sang J +6 more
europepmc +1 more source
Retroviruses and Diseases of the Nervous System [PDF]
openaire +2 more sources
Objective Studies of damage accrual in patients with systemic lupus erythematosus (SLE) show associations with disease activity measured by the SLE Disease Activity Index 2000 (SLEDAI‐2K), but these associations are imperfect. SLEDAI scores are powerfully influenced by weightings (1–8) assigned to each domain.
Kevin Zhang +8 more
wiley +1 more source
Study on the final diagnosis of nervous system diseases with psychiatric symptoms as manifestation onset. [PDF]
Li B, Guo W, Shang X.
europepmc +1 more source
TREK-1 in central nervous system diseases. [PDF]
Chen M, Wang Y, Xiong Z, Fang Y, Zhu Z.
europepmc +1 more source
An intrinsic photoactive star‐shaped zinc phtalocyanine‐poly(L‐glutamic acid) (ZnPc‐PGA) nanoplatform for multimodal glioblastoma (GBM) therapy and brain‐targeted elivery. A ZnPc‐PGA‐based multifunctional theranostic nanocarrier platform enables image‐guided, multimodal GBM therapy. ZnPc‐PGA nanocarriers support the integration of fluorescence imaging,
Amina Benaicha‐Fernández +14 more
wiley +1 more source
Autophagy-mediated regulation of neutrophil inflammatory responses and its relevance to central nervous system diseases. [PDF]
Li Y, Tan Y, Zuo W.
europepmc +1 more source

